What's new? Log in Free sign up

Purple Biotech (PPBT)

Company Profile

Company profile

Ticker

PPBT

Exchange

Website

purple-biotech.com

CEO

Mr. Gil Efron CPA, M.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Kitov Pharma Ltd., Kitov Pharmaceuticals Holdings Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PPBT stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Report of Foreign Private Issuer

Prospectus supplement for primary offering

Report of Foreign Private Issuer

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Report of Foreign Private Issuer

Prospectus supplement for primary offering

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Purple Biotech Reports Third Quarter 2024 Financial Results

Latest ownership filings

View all

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

CVI Investments, Inc.

SABBY MANAGEMENT, LLC

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

SABBY MANAGEMENT, LLC

Financial summary

Financial statements Chart PPBT financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PPBT institutional ownership history Ownership history

57.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	6	21	-71.4%
Opened positions	1	3	-66.7%
Closed positions	16	4	+300.0%
Increased positions	0	5	EXIT
Reduced positions	4	3	+33.3%

13F shares	Current	Prev Q	Change
Total value	903.90 mm	762.25 mm	+18.6%
Total shares	1.51 mm	3.24 mm	-53.4%
Total puts	0.00	0.00
Total calls	0.00	5.60 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
CVI Investments	1.35 mm	$5.14 mm	0.0%
Armistice Capital	158.00 k	$876.90 mm	-88.4%
BNP Paribas Arbitrage	3.68 k	$20.40 mm	NEW
TD Waterhouse Canada	200.00	$1.14 mm	-95.0%
JPM JPMorgan Chase & Co.	42.00	$234.00 k	-95.1%
Global Retirement Partners	16.00	$89.00 k	-95.2%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	158.00 k	-1.20 mm	-88.4%
Kingswood Wealth Advisors	0.00	-208.06 k	EXIT
MS Morgan Stanley	0.00	-203.00 k	EXIT
Citadel Advisors	0.00	-24.63 k	EXIT
Venture Visionary Partners	0.00	-22.16 k	EXIT
Virtu Financial	0.00	-19.27 k	EXIT
HRT Financial	0.00	-13.74 k	EXIT
UBS UBS	0.00	-12.85 k	EXIT
Geode Capital Management	0.00	-12.67 k	EXIT
Raymond James & Associates	0.00	-10.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Purple Biotech Teams Up with Mount Sinai to Boost Cancer Immunotherapy Research

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today that it

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Purple Biotech (PPBT) Stock Is Getting Hammered

Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Is Purple Biotech Stock Trading Higher On Monday?

Press releases

From Benzinga Pro

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types.CAPTN-3 antibodies are

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune

Purple Biotech Reports Third Quarter 2024 Financial Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.